Feng Wang

Presentation(s):

• SO-17: A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer

  Friday, July 1, 2022
  08:08 – 08:16